Reading view
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-z
Analysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.Surface-based Molecular Design with Multi-modal Flow Matching
Belief in Authority: Impact of Authority in Multi-Agent Evaluation Framework
Atlas 2 -- Foundation models for clinical deployment
PsychEval: A Multi-Session and Multi-Therapy Benchmark for High-Realism AI Psychological Counselor
A Web-Based Cancer Prevention Intervention for Rural Emerging Adults: Mixed Methods Development and Pilot-Testing Study
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
npj Digital Medicine, Published online: 07 January 2026; doi:10.1038/s41746-025-02324-4
An autonomous agentic workflow for clinical detection of cognitive concerns using large language modelsAdaptive therapy for perioperative non-small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment
Transl Oncol. 2026 Jan 6;64:102660. doi: 10.1016/j.tranon.2025.102660. Online ahead of print.
ABSTRACT
Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases. The low rate of early diagnosis and the high rate of occult metastases limit the survival benefits of conventional treatments. The current TNM staging system fails to fully reflect tumor heterogeneity or the dynamic molecular evolution of the disease, thus affecting the prediction of recurrence and the prognostic stratification. Some recent advances in minimal residual disease (MRD) detection, such as ultra-sensitive liquid biopsy technologies, have largely overcome the limitations of traditional imaging and offered a transformative approach for continuous, precision-based management of lung cancer. This review systematically summarized the technological evolution of MRD detection and highlighted its clinical significance in guiding adaptive therapy for NSCLC, including treatment escalation, de-escalation, and the emerging concept of precision-guided drug holidays. Moreover, the authors comprehensively discussed the "Four-Dimensional TNMB Staging System," which incorporates continuous molecular monitoring to address the static limitations of conventional staging and enhance the accuracy of prognostic stratification. Although ongoing challenges, such as the lack of standardized interpretation criteria and limited detection sensitivity, the combinations with the third-generation liquid biopsy platforms, multi-omics analyses, and multi-center prospective validation studies are expected to advance the clinical implementation of MRD-guided strategies. The paradigm change will enable the transition of NSCLC management from conventional standardized models to a precision-guided, closed-loop system of "monitoring-intervention-remonitoring," establishing a solid theoretical and practical foundation for comprehensive, molecularly driven management strategies.
PMID:41496417 | DOI:10.1016/j.tranon.2025.102660
Establishment and Optimization of a Patient-Reported Outcome–Based Electronic-Diary for Symptoms Evaluation in Patients With Gastroesophageal Reflux Disorder: Prospective Cohort Study
OpenNovelty: An LLM-powered Agentic System for Verifiable Scholarly Novelty Assessment
JMedEthicBench: A Multi-Turn Conversational Benchmark for Evaluating Medical Safety in Japanese Large Language Models
Deployability-Centric Infrastructure-as-Code Generation: Fail, Learn, Refine, and Succeed through LLM-Empowered DevOps Simulation
Wearable-informed generative digital avatars predict task-conditioned post-stroke locomotion
A minimally invasive dried blood spot biomarker test for the detection of Alzheimer’s disease pathology
Nature Medicine, Published online: 05 January 2026; doi:10.1038/s41591-025-04080-0
This multicenter study demonstrates use of dried and capillary blood as a minimally invasive, scalable approach for Alzheimer’s biomarker testing in research, with potential as a widely scalable population-based research approach, especially in resource-limited settings.A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer
npj Digital Medicine, Published online: 31 December 2025; doi:10.1038/s41746-025-02260-3
A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancerSciEvalKit: An Open-source Evaluation Toolkit for Scientific General Intelligence
From Model Choice to Model Belief: Establishing a New Measure for LLM-Based Research
PathFound: An Agentic Multimodal Model Activating Evidence-seeking Pathological Diagnosis
Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions
Ann Med. 2026 Dec;58(1):2607229. doi: 10.1080/07853890.2025.2607229. Epub 2025 Dec 26.
ABSTRACT
BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remaining the predominant etiological factors. Chronic viral infection not only drives carcinogenesis but also reshapes the hepatic immune microenvironment, profoundly influencing the efficacy and safety of immunotherapy.
RECENT ADVANCES: Immune checkpoint inhibitors (ICIs) have revolutionized systemic therapy for advanced HCC, with agents targeting PD-1/PD-L1 demonstrating clinical benefit. Combination strategies - such as ICIs with anti-angiogenic therapies, multikinase inhibitors, or locoregional treatments - have shown synergistic efficacy and are now standard of care in certain settings. For virus-related HCC, antiviral therapy improves immune responsiveness and reduces risks such as HBV reactivation, underscoring the need for integrated management.
FUTURE PERSPECTIVES: Emerging therapeutic approaches include next-generation immune checkpoints (e.g. TIM-3, LAG-3, TIGIT), bispecific antibodies, cellular therapies (CAR-T, TCR-T, TILs), and tumor vaccines targeting viral or tumor-associated antigens. Advances in biomarker discovery, including circulating tumor DNA, immune signatures, and microbiome modulation, are expected to guide personalized treatment. Integration of multi-omics and clinical data will further refine patient selection and optimize treatment sequencing.
CONCLUSION: Immunotherapy offers new hope for patients with virus-related HCC, but challenges remain in response heterogeneity, resistance, and toxicity. Individualized strategies that combine immunotherapy with effective antiviral management and biomarker-|guided patient selection are essential. Continued translational and clinical research into virus-immune-tumor interactions will enable safer, more effective, and more durable treatment outcomes, ultimately transforming HCC into a more manageable disease.
PMID:41454610 | PMC:PMC12777805 | DOI:10.1080/07853890.2025.2607229